Abstract
The feasibility of intensity modulated radiotherapy (IMRT) with involved field radiotherapy (IFRT) for Japanese patients with locally advanced non-small cell lung cancer (LA-NSCLC) remains unclear. Here we reviewed our initial experience of IMRT with IFRT for Japanese patients with LA-NSCLC to evaluate the feasibility of the treatment. Twenty LA-NSCLC patients who were treated with IMRT with IFRT during November 2019 to October 2020 were retrospectively analyzed. All patients received 60 Gy in 30 fractions of IMRT and were administered concurrent platinum-based chemotherapy. The median patient age was 71 years old and the group included 15 men and 5 women. The patient group included 2 patients with stage IIB, 11 patients with stage IIIA, 5 patients with stage IIIB, and 2 patients with stage IIIC disease. Histological diagnosis was squamous cell carcinoma in 14 patients, adenocarcinoma in 5 patients, and non-small cell lung cancer in 1 patient. The median follow-up period was 8 months. The incidence of grade 3 or greater pneumonitis was 5%, and grade 3 or greater esophagitis was not observed. None of the patients developed regional lymph node, with only recurrence reported so far. These findings indicate that IMRT with IFRT for Japanese patients with LA-NSCLC is feasible in terms of acute toxicity. Further study with a larger number of patients and longer follow-up to clarify the effect of treatment on patient prognosis is required.
Highlights
Lung cancer remains the leading cause of cancer-related mortality worldwide [1,2]
Patients with LA-Non-small cell lung cancer (NSCLC) who were treated by Intensity modulated radiotherapy (IMRT) with involved field radiotherapy (IFRT) between December 2019 and October 2020 were retrospectively analyzed under approval from our institutional review board
Patients and treatments A total of 20 LA-NSCLC patients who were treated by volumetric modulated arc therapy (VMAT) with IFRT were retrospectively analyzed
Summary
Lung cancer remains the leading cause of cancer-related mortality worldwide [1,2]. Non-small cell lung cancer (NSCLC) is a major pathological type of lung cancer which accounts for approximately 85% of lung cancer [3]. Concurrent chemo-radiotherapy (CCRT) is the standard treatment for inoperable locally advanced NSCLC (LANSCLC) [4]. Durvalumab as an maintenance therapy after CCRT has been proven to have good efficacy in patients with LANSCLC [5,6,7]. Radiotherapy techniques have been improved over the last decade, and high precision radiotherapy is available for various kinds of tumors [8].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.